Statistical Analysis of the Apparent Diffusion Coefficient in Patients with Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion Indicates That the Pathology Extends Well beyond the Visible Lesions
Identifieur interne : 000F14 ( Pmc/Corpus ); précédent : 000F13; suivant : 000F15Statistical Analysis of the Apparent Diffusion Coefficient in Patients with Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion Indicates That the Pathology Extends Well beyond the Visible Lesions
Auteurs : Yang Qing ; Wang Xiong ; Huang Da-Xiang ; Zhu Juan ; Wang Fei ; Yu Yong-QiangSource :
- Magnetic Resonance in Medical Sciences [ 1347-3182 ] ; 2019.
Abstract
To investigate whether the genu of the corpus callosum is involved in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) type I.
Twenty-three cases of clinically confirmed MERS I were analyzed retrospectively, and MRI features of the lesion were observed. The apparent diffusion coefficient (ADC) values of the same region of interests in lesions at the splenium and genu of the corpus callosum were measured before and after treatment (i.e., four groups), and the average ADC values were calculated. Paired
The mean ADC values of the splenium before and after treatment were 0.448 ± 0.124 and 0.790 ± 0.070 × 10−3 mm2/s, respectively, showing significant difference (
The genu showed a slight restriction in diffusion in the acute stage of type I MERS. After treatment, this diffusion restriction diminished as it typically does in the splenium. Our results indicate that the pathology in MERS extends well beyond the visible lesions.
Url:
DOI: 10.2463/mrms.mp.2018-0097
PubMed: 30956273
PubMed Central: 7067916
Links to Exploration step
PMC:7067916Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Statistical Analysis of the Apparent Diffusion Coefficient in Patients with Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion Indicates That the Pathology Extends Well beyond the Visible Lesions</title><author><name sortKey="Qing, Yang" sort="Qing, Yang" uniqKey="Qing Y" first="Yang" last="Qing">Yang Qing</name><affiliation><nlm:aff id="AFF1">Department of MRI, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Xiong, Wang" sort="Xiong, Wang" uniqKey="Xiong W" first="Wang" last="Xiong">Wang Xiong</name><affiliation><nlm:aff id="AFF2">Department of Neurology, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Da Xiang, Huang" sort="Da Xiang, Huang" uniqKey="Da Xiang H" first="Huang" last="Da-Xiang">Huang Da-Xiang</name><affiliation><nlm:aff id="AFF3">Department of Endocrinology, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Juan, Zhu" sort="Juan, Zhu" uniqKey="Juan Z" first="Zhu" last="Juan">Zhu Juan</name><affiliation><nlm:aff id="AFF1">Department of MRI, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Fei, Wang" sort="Fei, Wang" uniqKey="Fei W" first="Wang" last="Fei">Wang Fei</name><affiliation><nlm:aff id="AFF1">Department of MRI, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Yong Qiang, Yu" sort="Yong Qiang, Yu" uniqKey="Yong Qiang Y" first="Yu" last="Yong-Qiang">Yu Yong-Qiang</name><affiliation><nlm:aff id="AFF4">The First Affiliated Hospital of Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">30956273</idno><idno type="pmc">7067916</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067916</idno><idno type="RBID">PMC:7067916</idno><idno type="doi">10.2463/mrms.mp.2018-0097</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000F14</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000F14</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Statistical Analysis of the Apparent Diffusion Coefficient in Patients with Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion Indicates That the Pathology Extends Well beyond the Visible Lesions</title><author><name sortKey="Qing, Yang" sort="Qing, Yang" uniqKey="Qing Y" first="Yang" last="Qing">Yang Qing</name><affiliation><nlm:aff id="AFF1">Department of MRI, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Xiong, Wang" sort="Xiong, Wang" uniqKey="Xiong W" first="Wang" last="Xiong">Wang Xiong</name><affiliation><nlm:aff id="AFF2">Department of Neurology, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Da Xiang, Huang" sort="Da Xiang, Huang" uniqKey="Da Xiang H" first="Huang" last="Da-Xiang">Huang Da-Xiang</name><affiliation><nlm:aff id="AFF3">Department of Endocrinology, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Juan, Zhu" sort="Juan, Zhu" uniqKey="Juan Z" first="Zhu" last="Juan">Zhu Juan</name><affiliation><nlm:aff id="AFF1">Department of MRI, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Fei, Wang" sort="Fei, Wang" uniqKey="Fei W" first="Wang" last="Fei">Wang Fei</name><affiliation><nlm:aff id="AFF1">Department of MRI, Anqing Municipal Hospital, Anhui, China</nlm:aff></affiliation></author><author><name sortKey="Yong Qiang, Yu" sort="Yong Qiang, Yu" uniqKey="Yong Qiang Y" first="Yu" last="Yong-Qiang">Yu Yong-Qiang</name><affiliation><nlm:aff id="AFF4">The First Affiliated Hospital of Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China</nlm:aff></affiliation></author></analytic><series><title level="j">Magnetic Resonance in Medical Sciences</title><idno type="ISSN">1347-3182</idno><idno type="eISSN">1880-2206</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose:</title><p>To investigate whether the genu of the corpus callosum is involved in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) type I.</p></sec><sec><title>Methods:</title><p>Twenty-three cases of clinically confirmed MERS I were analyzed retrospectively, and MRI features of the lesion were observed. The apparent diffusion coefficient (ADC) values of the same region of interests in lesions at the splenium and genu of the corpus callosum were measured before and after treatment (i.e., four groups), and the average ADC values were calculated. Paired <italic>t</italic>-tests were used to compare the ADC values of lesions in the splenium and genu before and after treatment. Independent sample <italic>t</italic>-tests were used to compare the values in the splenium and genu after treatment.</p></sec><sec><title>Results:</title><p>The mean ADC values of the splenium before and after treatment were 0.448 ± 0.124 and 0.790 ± 0.070 × 10<sup>−3</sup> mm<sup>2</sup>/s, respectively, showing significant difference (<italic>P</italic> < 0.01). The mean ADC values in the genu before and after treatment were 0.783 ± 0.067 and 0.829 ± 0.070 × 10<sup>−3</sup> mm<sup>2</sup>/s, respectively, also showing significant difference (<italic>P</italic> < 0.01). There was no significant difference in the ADC values between the splenium and genu after treatment (<italic>P</italic> > 0.05).</p></sec><sec><title>Conclusion:</title><p>The genu showed a slight restriction in diffusion in the acute stage of type I MERS. After treatment, this diffusion restriction diminished as it typically does in the splenium. Our results indicate that the pathology in MERS extends well beyond the visible lesions.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Tada, H" uniqKey="Tada H">H Tada</name></author><author><name sortKey="Takanashi, J" uniqKey="Takanashi J">J Takanashi</name></author><author><name sortKey="Barkovich, Aj" uniqKey="Barkovich A">AJ Barkovich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takanashi, J" uniqKey="Takanashi J">J Takanashi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia Monco, Jc" uniqKey="Garcia Monco J">JC Garcia-Monco</name></author><author><name sortKey="Cortina, Ie" uniqKey="Cortina I">IE Cortina</name></author><author><name sortKey="Ferreira, E" uniqKey="Ferreira E">E Ferreira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Starkey, J" uniqKey="Starkey J">J Starkey</name></author><author><name sortKey="Kobayashi, N" uniqKey="Kobayashi N">N Kobayashi</name></author><author><name sortKey="Numaguchi, Y" uniqKey="Numaguchi Y">Y Numaguchi</name></author><author><name sortKey="Moritani, T" uniqKey="Moritani T">T Moritani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takanashi, J" uniqKey="Takanashi J">J Takanashi</name></author><author><name sortKey="Imamura, A" uniqKey="Imamura A">A Imamura</name></author><author><name sortKey="Hayakawa, F" uniqKey="Hayakawa F">F Hayakawa</name></author><author><name sortKey="Terada, H" uniqKey="Terada H">H Terada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marsala, Sz" uniqKey="Marsala S">SZ Marsala</name></author><author><name sortKey="Antichi, E" uniqKey="Antichi E">E Antichi</name></author><author><name sortKey="Pistacchi, M" uniqKey="Pistacchi M">M Pistacchi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dardzinski, Bj" uniqKey="Dardzinski B">BJ Dardzinski</name></author><author><name sortKey="Sotak, Ch" uniqKey="Sotak C">CH Sotak</name></author><author><name sortKey="Fisher, M" uniqKey="Fisher M">M Fisher</name></author><author><name sortKey="Hasegawa, Y" uniqKey="Hasegawa Y">Y Hasegawa</name></author><author><name sortKey="Li, L" uniqKey="Li L">L Li</name></author><author><name sortKey="Minematsu, K" uniqKey="Minematsu K">K Minematsu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aksu, B" uniqKey="Aksu B">B Aksu</name></author><author><name sortKey="Kurtcan, S" uniqKey="Kurtcan S">S Kurtcan</name></author><author><name sortKey="Alkan, A" uniqKey="Alkan A">A Alkan</name></author><author><name sortKey="Aralasmak, A" uniqKey="Aralasmak A">A Aralasmak</name></author><author><name sortKey="Oktem, F" uniqKey="Oktem F">F Oktem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, Yw" uniqKey="Lin Y">YW Lin</name></author><author><name sortKey="Yu, Cy" uniqKey="Yu C">CY Yu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tsubouchi, Y" uniqKey="Tsubouchi Y">Y Tsubouchi</name></author><author><name sortKey="Itamura, S" uniqKey="Itamura S">S Itamura</name></author><author><name sortKey="Saito, Y" uniqKey="Saito Y">Y Saito</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sun, D" uniqKey="Sun D">D Sun</name></author><author><name sortKey="Chen, Wh" uniqKey="Chen W">WH Chen</name></author><author><name sortKey="Baralc, S" uniqKey="Baralc S">S Baralc</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Osuka, S" uniqKey="Osuka S">S Osuka</name></author><author><name sortKey="Imai, H" uniqKey="Imai H">H Imai</name></author><author><name sortKey="Ishikawa, E" uniqKey="Ishikawa E">E Ishikawa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Badaut, J" uniqKey="Badaut J">J Badaut</name></author><author><name sortKey="Fukuda, Am" uniqKey="Fukuda A">AM Fukuda</name></author><author><name sortKey="Jullienne, A" uniqKey="Jullienne A">A Jullienne</name></author><author><name sortKey="Petry, Kg" uniqKey="Petry K">KG Petry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ito, H" uniqKey="Ito H">H Ito</name></author><author><name sortKey="Yamamoto, N" uniqKey="Yamamoto N">N Yamamoto</name></author><author><name sortKey="Arima, H" uniqKey="Arima H">H Arima</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, B" uniqKey="Yang B">B Yang</name></author><author><name sortKey="Zador, Z" uniqKey="Zador Z">Z Zador</name></author><author><name sortKey="Verkman, As" uniqKey="Verkman A">AS Verkman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hubbard, Ja" uniqKey="Hubbard J">JA Hubbard</name></author><author><name sortKey="Hsu, Ms" uniqKey="Hsu M">MS Hsu</name></author><author><name sortKey="Seldin, Mm" uniqKey="Seldin M">MM Seldin</name></author><author><name sortKey="Binder, Dk" uniqKey="Binder D">DK Binder</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, H" uniqKey="Lu H">H Lu</name></author><author><name sortKey="Hu, H" uniqKey="Hu H">H Hu</name></author><author><name sortKey="He, Zp" uniqKey="He Z">ZP He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, C" uniqKey="Yang C">C Yang</name></author><author><name sortKey="Liu, Z" uniqKey="Liu Z">Z Liu</name></author><author><name sortKey="Li, H" uniqKey="Li H">H Li</name></author><author><name sortKey="Zhai, F" uniqKey="Zhai F">F Zhai</name></author><author><name sortKey="Liu, J" uniqKey="Liu J">J Liu</name></author><author><name sortKey="Bian, J" uniqKey="Bian J">J Bian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Katada, R" uniqKey="Katada R">R Katada</name></author><author><name sortKey="Nishitani, Y" uniqKey="Nishitani Y">Y Nishitani</name></author><author><name sortKey="Honmou, O" uniqKey="Honmou O">O Honmou</name></author><author><name sortKey="Zhai, F" uniqKey="Zhai F">F Zhai</name></author><author><name sortKey="Liu, J" uniqKey="Liu J">J Liu</name></author><author><name sortKey="Bian, J" uniqKey="Bian J">J Bian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arima, H" uniqKey="Arima H">H Arima</name></author><author><name sortKey="Yamamoto, N" uniqKey="Yamamoto N">N Yamamoto</name></author><author><name sortKey="Sobue, K" uniqKey="Sobue K">K Sobue</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ribeiro Mde, C" uniqKey="Ribeiro Mde C">C Ribeiro Mde</name></author><author><name sortKey="Hirt, L" uniqKey="Hirt L">L Hirt</name></author><author><name sortKey="Bogousslavsky, J" uniqKey="Bogousslavsky J">J Bogousslavsky</name></author><author><name sortKey="Regli, L" uniqKey="Regli L">L Regli</name></author><author><name sortKey="Badaut, J" uniqKey="Badaut J">J Badaut</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Colbran, Rj" uniqKey="Colbran R">RJ Colbran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huber, Vj" uniqKey="Huber V">VJ Huber</name></author><author><name sortKey="Tsujita, M" uniqKey="Tsujita M">M Tsujita</name></author><author><name sortKey="Kwee, Il" uniqKey="Kwee I">IL Kwee</name></author><author><name sortKey="Nakada, T" uniqKey="Nakada T">T Nakada</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Magn Reson Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Magn Reson Med Sci</journal-id><journal-id journal-id-type="publisher-id">mrms</journal-id><journal-title-group><journal-title>Magnetic Resonance in Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1347-3182</issn><issn pub-type="epub">1880-2206</issn><publisher><publisher-name>Japanese Society for Magnetic Resonance in Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30956273</article-id><article-id pub-id-type="pmc">7067916</article-id><article-id pub-id-type="doi">10.2463/mrms.mp.2018-0097</article-id><article-id pub-id-type="publisher-id">mrms-19-14</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Paper</subject></subj-group></article-categories><title-group><article-title>Statistical Analysis of the Apparent Diffusion Coefficient in Patients with Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion Indicates That the Pathology Extends Well beyond the Visible Lesions</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Qing</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Da-xiang</surname><given-names>Huang</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Juan</surname><given-names>Zhu</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fei</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yong-qiang</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref><xref ref-type="corresp" rid="C1"><sup>*</sup></xref></contrib><aff id="AFF1"><label>1</label>Department of MRI, Anqing Municipal Hospital, Anhui, China</aff><aff id="AFF2"><label>2</label>Department of Neurology, Anqing Municipal Hospital, Anhui, China</aff><aff id="AFF3"><label>3</label>Department of Endocrinology, Anqing Municipal Hospital, Anhui, China</aff><aff id="AFF4"><label>4</label>The First Affiliated Hospital of Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China</aff></contrib-group><author-notes><corresp id="C1"><label>*</label>Corresponding author, E-mail: <email>yongqiang_yu@sohu.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>05</day><month>4</month><year>2019</year></pub-date><volume>19</volume><issue>1</issue><fpage>14</fpage><lpage>20</lpage><history><date date-type="received"><day>06</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>© 2019 Japanese Society for Magnetic Resonance in Medicine</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><abstract><sec><title>Purpose:</title><p>To investigate whether the genu of the corpus callosum is involved in patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) type I.</p></sec><sec><title>Methods:</title><p>Twenty-three cases of clinically confirmed MERS I were analyzed retrospectively, and MRI features of the lesion were observed. The apparent diffusion coefficient (ADC) values of the same region of interests in lesions at the splenium and genu of the corpus callosum were measured before and after treatment (i.e., four groups), and the average ADC values were calculated. Paired <italic>t</italic>-tests were used to compare the ADC values of lesions in the splenium and genu before and after treatment. Independent sample <italic>t</italic>-tests were used to compare the values in the splenium and genu after treatment.</p></sec><sec><title>Results:</title><p>The mean ADC values of the splenium before and after treatment were 0.448 ± 0.124 and 0.790 ± 0.070 × 10<sup>−3</sup> mm<sup>2</sup>/s, respectively, showing significant difference (<italic>P</italic> < 0.01). The mean ADC values in the genu before and after treatment were 0.783 ± 0.067 and 0.829 ± 0.070 × 10<sup>−3</sup> mm<sup>2</sup>/s, respectively, also showing significant difference (<italic>P</italic> < 0.01). There was no significant difference in the ADC values between the splenium and genu after treatment (<italic>P</italic> > 0.05).</p></sec><sec><title>Conclusion:</title><p>The genu showed a slight restriction in diffusion in the acute stage of type I MERS. After treatment, this diffusion restriction diminished as it typically does in the splenium. Our results indicate that the pathology in MERS extends well beyond the visible lesions.</p></sec></abstract><kwd-group><kwd>apparent diffusion coefficient value</kwd><kwd>corpus callosum</kwd><kwd>magnetic resonance imaging</kwd><kwd>clinically mild encephalitis/encephalopathy with reversible splenial lesion</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) is a clinico-radiological syndrome first reported by Tada et al.,<sup><xref rid="B1" ref-type="bibr">1</xref></sup> and subsequently further described by Takanashi et al.,<sup><xref rid="B2" ref-type="bibr">2</xref></sup> and Garcia-Monco et al.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> described the clinical imaging syndrome in detail and proposed a new name, “reversible splenial lesion syndrome (RESLES)”. The cause of and mechanism underlying this disease are not completely clear. In most cases, the clinical and imaging abnormalities of MERS are reversible. However, in some cases (such as in patients with severe hypoglycemia), if it is not treated in time, marked central nervous system damage may occur; therefore, Starkey et al.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> suggested that the syndrome be named as “cytotoxic lesions of the corpus callosum,” to highlight the partial irreversibility of the disease. Takanashi et al.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> proposed dividing MERS into two types based on the extent of the lesion: type I lesions are limited to the splenium of the corpus callosum (SCC) on MR images, while type II lesions spread to the entire corpus callosum, adjacent white matter or both. They further speculated that type I had undergone a type II process, or that other parts of the corpus callosum (i.e., the body and the genu) and adjacent white matter were only slightly involved and could not be seen in routine diffusion-weighted imaging (DWI). This hypothesis has not been confirmed by experiments. However, understanding the actual extent of MERS is an important step toward understanding the pathology of this disease.</p><p>The purpose of this study is to verify or disprove Takanashi et al.’s hypothesis<sup><xref rid="B5" ref-type="bibr">5</xref></sup> about the range of MERS lesions. We thus performed a retrospective review of the medical and MRI records of 23 patients identified as having “MERS type I” or “RESLES type I.” The mean apparent diffusion coefficient (ADC) values of the SCC and genu of the corpus callosum (GCC) before and after treatment were quantitatively measured and compared.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec sec-type="subjects"><title>Patients</title><p>This study was approved by the Institutional Review Board before initiation (Decision No. 2017-01-001). The requirement for informed consent was waived because of the retrospective study design.</p><p>Twenty-three patients with MERS type I were identified in a tertiary referral hospital from January 2012 to November 2017 using a radiological database and their clinical and radiologic data were reviewed. These patients included 8 males and 15 females, with age at diagnosis ranging from 2 to 63 years, mean age: 16 ± 8.0 years. Eleven cases (47.83%) involved children. These 23 patients were diagnosed with MERS type I, based on the following criteria as set forth by Garcia-Monco et al.<sup><xref rid="B3" ref-type="bibr">3</xref></sup>: 1) neurological symptoms and signs such as headache, weakness of the limbs, aphasia, loss of consciousness, etc.; 2) MRI images showing cytotoxic edema in typical locations (lesions limited to the SCC); 3) both the imaging findings and clinical symptoms were reversible with treatment.</p></sec><sec><title>MRI equipment and scanning parameters</title><p>For MRI, we used a 3T superconducting magnetic resonance system (Discovery MR750, General Electric Healthcare, Milwaukee, IL, USA) and a standard 8-channel head coil. The sequences and parameters were: transverse T<sub>1</sub>WI-fluid-attenuated inversion recovery (FLAIR); transverse and sagittal T<sub>2</sub>WI-periodically rotated overlapping parallel lines with enhanced reconstruction (PROPELLER); transverse DWI (echo-planar imaging sequence, <italic>b</italic>-value set as 0, 1000 s/mm<sup>2</sup>; TR = 3000 ms, TE = 97 ms, FOV, 240 × 240 mm; matrix = 160 × 160, slice thickness = 5.5 mm; intersection gap = 1.5 mm; number of excitations = 2), and ADC-Map. The automatic head scan software-READY Brain (General Electric) was used in the follow-up MR scanning process to avoid layer interleaving. The interval between the appearance of clinical symptoms and the first MRI examination was 1–11 days, with an average of 3.9 days. The interval between the first MRI examination and the first follow-up was 5–29 days, with an average of 10.3 days.</p></sec><sec sec-type="methods"><title>Image processing and analysis</title><p>Two radiologists, each with more than 5 years of experience, confirmed the anatomical locations of the lesions and the abnormal signal intensities on T<sub>1</sub>WI, T<sub>2</sub>-WI, DWI, and ADC-map scans by cross-checking on an AW4.6 workstation (General Electric Healthcare). The ADC values were measured using Functool-ADC software (General Electric Healthcare). ROIs were automatically generated by the Functool-ADC software (round shape, 58 mm<sup>2</sup>), and the ROIs were carefully copied and placed in the center of the GCC and SCC (<xref ref-type="fig" rid="F1">Fig. 1</xref>); this was jointly confirmed by two radiologists. To avoid layer interleaving during the follow-up examination, we used the automatic head-scan software READY Brain (General Electric Healthcare), in follow-up MR scans. Four groups of ADC values were measured and recorded: SCC in the initial examination (group 1), SCC in the first follow-up examination after treatment (group 2), GCC in the initial examination (group 3), and GCC in the first follow-up examination after treatment (group 4); each of the ROIs’ ADC values were measured by two radiologists, independently. If the data obtained from the same ROI by each radiologist differed, the average value was used for the statistical analysis.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>The four groups of ADC values were statistically analyzed using IBM SPSS Statistics, version 19.0 (IBM Corporation, Armonk, NY, USA). Data conforming to a normal distribution are expressed as mean ± standard deviation. Paired <italic>t</italic>-tests were used to compare the means of groups 1 and 2, and of groups 3 and 4. Independent sample <italic>t</italic>-tests were used to compare the means of groups 2 and 4. Results with <italic>P</italic> < 0.05 were considered statistically significant. Statistical results are given to an accuracy of three decimal places.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The clinical data and radiological images of 23 patients were reviewed by all authors together. The basic information and clinical findings of the patients are summarized in <xref rid="T1" ref-type="table">Tables 1</xref> and <xref rid="T2" ref-type="table">2</xref>. One of the patients with diabetes who also showed hyperthyroidism, was counted once for statistical analysis. Six patients (26.08%) developed hyponatremia (mean serum sodium value: 131.7 ± 4.1 mmol/L; normal range, 135–145 mmol/L) during the course of their disease, but no patient developed hypokalemia. One patient showed severe hyponatremia (serum sodium: 123 mmol/L).</p><p>In the initial MRI examination, a total of 23 lesions were found in 23 MERS type I patients. The morphology and MR features of the lesions are summarized in <xref rid="T3" ref-type="table">Table 3</xref>. Based on the morphology, lesions of the SCC in MERS type I patients could be categorized into three forms: circle-shaped (seven cases, 30.43%, <xref ref-type="fig" rid="F2">Fig. 2a</xref>), oval-shaped (13 cases, 56.52%, <xref ref-type="fig" rid="F2">Fig. 2b</xref>), and boomerang-shaped (three cases, 13.04%, <xref ref-type="fig" rid="F2">Fig. 2c</xref>). DWI showed augmented signals (23 cases, 100%), and the ADC-map showed diminished signals (23 cases, 100%). The 23 lesions had disappeared completely (100%) by the follow-up MR examination.</p><p>For the 23 MERS type I cases, the mean ADC value, the standard deviation, the <italic>P</italic>-value and the results of paired <italic>t</italic>-tests for the same ROIs in the SCC and GCC before and after treatment are shown in <xref rid="T4" ref-type="table">Table 4</xref>. The ADC values of the SCC before and after treatment differed as statistically significant (<italic>t</italic> = −12.157, <italic>P</italic> = 3.096 × 10<sup>−11</sup>). The ADC values of the GCC before and after treatment were also differed as statistically significant (<italic>t</italic> = −4.780, <italic>P</italic> = 9.000 × 10<sup>−5</sup>). ADC values in the SCC and GCC after treatment did not differ statistically significant (<italic>t</italic> = −1.907, <italic>P</italic> = 0.063). <xref ref-type="fig" rid="F3">Figure 3</xref> shows a box plot for a visual comparison of the median, four quartiles, and extreme values (maximum and minimum values) of the four sets of data.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, we found that in the acute phase, the SCC showed high-intensity lesions that were typically symmetrical without enhancement on T<sub>2</sub> and diffusion-weighted sequences. The lesions showed ADC value reduction on ADC-maps.</p><p>In general, MERS lesions showed cytotoxic edema in typical anatomical locations, and the lesions usually disappeared from the MRI scans within a week or a few weeks (<xref rid="T1" ref-type="table">Table 1</xref> and <xref ref-type="fig" rid="F4">Fig. 4</xref>). There has been at least one report of lesions not disappearing for months,<sup><xref rid="B6" ref-type="bibr">6</xref></sup> but we did not encounter such delayed disappearance in this study.</p><p>The mean ADC value of lesions in the SCC before treatment was 0.448 ± 0.124 × 10<sup>−3</sup> mm<sup>2</sup>/s. After treatment, the mean ADC value of lesions in the SCC was increased to 0.790 ± 0.070 × 10<sup>−3</sup> mm<sup>2</sup>/s (<xref rid="T4" ref-type="table">Table 4</xref>). These changes in ADC values of lesions in the SCC of MERS patients after treatment were statistically significant. Dardzinski et al.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> argued that lesions may be reversible when the ADC value of the lesion is 0.450–0.550 × 10<sup>−3</sup> mm<sup>2</sup>/s, but if the value was lower than this threshold, the lesion was not reversible. In our study, all lesions in the 23 MERS patients were reversed by treatment. Even, a lesion with an ADC value of 0.260 × 10<sup>−3</sup> mm<sup>2</sup>/s, occurring in one patient, was still reversible. Thus, when using the ADC value to judge the prognosis of MERS, it is necessary to consider that different pathological mechanisms may yield different results.</p><p>The extreme (maximum) values (patient No. 20) in the box plots (<xref ref-type="fig" rid="F3">Fig. 3</xref>, star symbol) were obtained in the initial MRI examinations on day 11 after the appearance of clinical symptoms (corresponding to <xref rid="T1" ref-type="table">Table 1</xref>, patient No. 20). As previously reported in the literature, SCC signal abnormalities may reduce most rapidly within 2 days of the initial MR examination.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> This patient (No. 20) may therefore have been in the recovery period, so that diffusion was restricted in the shrinking lesions (yielding a high ADC value).</p><p>It should be noted that the patients included in this study were diagnosed with MERS type I (100%). Although the lesions in type I MERS were diverse (<xref rid="T3" ref-type="table">Table 3</xref> and <xref ref-type="fig" rid="F2">Fig. 2</xref>), none of the lesions on conventional MR (including DWI and ADC-map) images were found outside the SCC region. However, if Takanashi et al.’s<sup><xref rid="B5" ref-type="bibr">5</xref></sup> speculations are correct, a statistical analysis of the ADC values of the GCC should make it possible to detect the same ADC value changes that are seen in the SCC (albeit mild). Quantitative measurements and statistical analyses in this study found that in the acute stage of MERS, not only the SCC, but also the GCC region showed mild diffusion restriction (an ADC value decrease), which is not easy to detect. GCC diffusion restriction showed a recovery, as it does in the SCC after a period of time (<xref rid="T4" ref-type="table">Table 4</xref>). In previous studies,<sup><xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B8" ref-type="bibr">8</xref></sup> diffusion restriction was not detected in the GCC in patients with MERS type I, probably because the signal changes were minor and not easily detected by human eyes.</p><p>Clinically, the syndrome is associated with a wide spectrum of conditions. The neurological symptoms of MERS usually resolve completely, without neurological sequelae after a short disease course.<sup><xref rid="B3" ref-type="bibr">3</xref></sup> However, the underlying pathophysiological mechanism of MERS remains unclear. Takanashi et al.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> proposed that the type I lesions are limited to the SCC on MR images, while type II lesions spread to the entire corpus callosum, adjacent white matter or both. They further speculated that MERS type II resolved completely by passing through a MERS type I stage exhibiting an isolated splenial lesion, or that other parts of the corpus callosum and adjacent white matter were only minimally involved and changes in these regions could not be detected by routine DWI. Our research adds evidence supporting this speculation. Lin et al.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> reported the case of a 36-year-old male patient with MERS type I, with <italic>Staphylococcus aureus</italic> meningitis, whose NAA/Cr, NAA/Cho, and Cho/Cr ratios were abnormal in all examined regions of the brain, suggesting that the pathological changes in MERS actually involve the entire brain. Tsubouchi et al.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> reported that the range of lesions in high <italic>b</italic>-value (<italic>b</italic> = 3000) DWI was larger than that seen with conventional <italic>b</italic>-value (<italic>b</italic> = 1000) DWI (six cases), and in one case, lesions were observed within a high <italic>b</italic> value (<italic>b</italic> = 3000) that could not be seen with conventional <italic>b</italic> values (<italic>b</italic> = 1000). They did not statistically analyze their results. However, taking these results together with those of our study, we believe that the area involved in MERS lesions may be broader than previously recognized. That is to say, the pathology in MERS appears to extend well beyond the visible lesions.</p><p>Neonatal MERS cases have been described by Sun et al.<sup><xref rid="B11" ref-type="bibr">11</xref></sup> Since neonates can develop the disease even though their myelin sheaths are not yet developed, we speculate that the pathological changes in MERS are actually located in astrocytes rather than inside or beneath myelin as previously thought,<sup><xref rid="B12" ref-type="bibr">12</xref></sup> this is also suggested by the study of Starkey et al.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> We further speculate that the reason for varying ADC values (cytotoxic edema) in the SCC and GCC of MERS patients is that the corpus callosum may have a special receptor or protein gradient from the posterior to the anterior. The receptor or protein most likely to be involved is aquaporin 4 (AQP4). To the best of our knowledge, no existing experiments are exactly on the gradient difference of AQP4 receptor/protein in corpus callosum. However, it is still some relevant evidence to support this speculation: Aquaporins (AQPs) are an evolutionarily conserved family of membrane transporter proteins that regulate the flow of water and in some cases, glycerol and other small molecules across cellular membranes.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> AQP4-knockout mice show a decrease in cytotoxic brain edema after water intoxication and focal cerebral ischemia,<sup><xref rid="B14" ref-type="bibr">14</xref></sup> and AQP4-overexpressing mice show accelerated progression of cytotoxic brain edema.<sup><xref rid="B15" ref-type="bibr">15</xref></sup> These findings suggest that AQP4 contributes to the development of cytotoxic brain edema. A high concentration of AQP4 is found on astrocyte end-feet in contact with all blood vessels and astrocyte. The AQP4 distribution differs significantly within brain structures such as the hippocampus, the brainstem and particularly the corpus callosum.<sup><xref rid="B16" ref-type="bibr">16</xref></sup> Badaut et al.<sup><xref rid="B13" ref-type="bibr">13</xref></sup> reported that at high magnification, AQP4 staining in the corpus callosum reveals that AQP4 has “patchy” distribution, following the direction of the neuronal processes. This higher density leads to a tendency for the development of cytotoxic edema in the corpus callosum to develop when cytokinopathy occurs.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> Lu et al.<sup><xref rid="B17" ref-type="bibr">17</xref></sup> investigated the correlations among DWI, histopathology and AQP4 expression in the rat brain that was re-perfused after acute ischemia. They found a close correlation between AQP4 expression and the cerebral intracellular edema, and that AQP4 messenger Ribonucleic acid (mRNA) expression was negatively correlated with regional ADC values. This correlation has also been reported elsewhere.<sup><xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref></sup> That altered ADC values may indirectly reflect the level of AQP4 expression. Various of conditions such as infection, sudden discontinuation of anti-epileptic drugs, endocrine abnormalities, and drug toxic effects, etc. which have been reported to trigger MERS, can also affect the AQP4 protein expression, leading to increased expression levels through a complex cell-cytokine<sup><xref rid="B4" ref-type="bibr">4</xref></sup> or an intracranial microenvironment osmotic mechanism.<sup><xref rid="B20" ref-type="bibr">20</xref></sup> AQP4 channel activation will result in an influx of water into astrocytes, resulting in intracellular edema and reduced diffusion (cytotoxic edema). The link between AQP4 and MERS could be indirectly tested or explained by a series of experiments and studies.<sup><xref rid="B13" ref-type="bibr">13</xref>–<xref rid="B23" ref-type="bibr">23</xref></sup> This pathogenic mechanism for MERS has not previously been proposed.</p><p>There are some limitations to our study. First, the number of subjects was relatively small. Further studies with a larger number of patients are necessary to confirm our results. Second, the body of the corpus callosum was not quantitatively measured in our study, because it is difficult to locate it in transverse diffusion imaging. However, it is much easier to locate in sagittal imaging. Therefore, sagittal DWI should be performed for MERS patients in future studies, to measure and evaluate ADC value changes and differences in all three parts of the corpus callosum (genu, body, and splenium) simultaneously. In theory, the lesion may extend to the occipital lobe (associated with the bilateral occipital forceps), the basal ganglia (associated with the corpus callosum fibers), a large portion of the parietal lobe, and even the hippocampus and the brainstem. Determining the true extent of the lesion warrants further study.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Our results showed that the genu of the corpus callosum shows a slight diffusion restriction in the acute stage of type I MERS, but that this recovers after treatment, as it does in the splenium of the callosum. We suggest that the lesions in type I MERS may be more widespread than previously thought. The results of this study call for further research.</p></sec><sec><title>Explanation of Technical Terms</title><sec><title>READY Brain</title><p>The READY Brain protocol acquires a 3D localizer that calculates the brain center. The location of the anterior of corpus callosum (AC) and the posterior of the corpus callosum (PC) has some correlates with somewhat with the shape of the head and the anatomy of the individual patient. The system calculates the localizer for the AC–PC line from a 3D data set that is named as the Registration Localizer (READY Brain 3D Loc), which uses 3D and 2D matching technology. When Auto-Scan is added to this, it provides a one-touch protocol. READY Brain calculates the angle of the scan plane that is closest to the plane determined by the AC–PC line. Ready Brain also calculates the center of the brain, which is not necessarily the same as the mid-point of AC and PC. It is a useful tool, similar to the DOT-Brain software from Siemens Healthcare (Erlangen, Germany).</p></sec></sec></body><back><fn-group><fn><p><bold>Funding</bold></p><p>The study and collection work was funded by the Anqing Science and Technology Bureau (2018Z2018).</p></fn><fn fn-type="COI-statement"><p><bold>Conflicts of Interest</bold></p><p>The authors declare no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tada</surname><given-names>H</given-names></name><name><surname>Takanashi</surname><given-names>J</given-names></name><name><surname>Barkovich</surname><given-names>AJ</given-names></name><etal></etal></person-group><article-title>Clinically mild encephalitis/encephalopathy with a reversible splenial lesion</article-title>. <source>Neurology</source><year>2004</year>; <volume>63</volume>:<fpage>1854</fpage>–<lpage>1858</lpage>.<pub-id pub-id-type="pmid">15557501</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takanashi</surname><given-names>J</given-names></name></person-group><article-title>Two newly proposed infectious encephalitis/encephalopathy syndromes</article-title>. <source>Brain Dev</source><year>2009</year>; <volume>31</volume>:<fpage>521</fpage>–<lpage>528</lpage>.<pub-id pub-id-type="pmid">19339128</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Monco</surname><given-names>JC</given-names></name><name><surname>Cortina</surname><given-names>IE</given-names></name><name><surname>Ferreira</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Reversible splenial lesion syndrome (RESLES): what’s in a name?</article-title><source>J Neuroimaging</source><year>2011</year>; <volume>21</volume>:<fpage>e1</fpage>–<lpage>e14</lpage>.<pub-id pub-id-type="pmid">18681931</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starkey</surname><given-names>J</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Numaguchi</surname><given-names>Y</given-names></name><name><surname>Moritani</surname><given-names>T</given-names></name></person-group><article-title>Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations</article-title>. <source>Radiographics</source><year>2017</year>; <volume>37</volume>:<fpage>562</fpage>–<lpage>576</lpage>.<pub-id pub-id-type="pmid">28165876</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takanashi</surname><given-names>J</given-names></name><name><surname>Imamura</surname><given-names>A</given-names></name><name><surname>Hayakawa</surname><given-names>F</given-names></name><name><surname>Terada</surname><given-names>H</given-names></name></person-group><article-title>Differences in the time course of splenial and white matter lesions in clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)</article-title>. <source>J Neurol Sci</source><year>2010</year>; <volume>292</volume>:<fpage>24</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">20236662</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsala</surname><given-names>SZ</given-names></name><name><surname>Antichi</surname><given-names>E</given-names></name><name><surname>Pistacchi</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Mild encephalitis with a reversible splenial lesion: a clinical benign condition, often underrecognized - Clinical case and literature review</article-title>. <source>J Neurosci Rural Pract</source><year>2017</year>; <volume>8</volume>:<fpage>281</fpage>–<lpage>283</lpage>.<pub-id pub-id-type="pmid">28479809</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dardzinski</surname><given-names>BJ</given-names></name><name><surname>Sotak</surname><given-names>CH</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Minematsu</surname><given-names>K</given-names></name></person-group><article-title>Apparent diffusion coefficient mapping of experimental focal cerebral ischemia using diffusion-weighted echo-planar imaging</article-title>. <source>Magn Reson Med</source><year>1993</year>; <volume>30</volume>:<fpage>318</fpage>–<lpage>325</lpage>.<pub-id pub-id-type="pmid">8412602</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksu</surname><given-names>B</given-names></name><name><surname>Kurtcan</surname><given-names>S</given-names></name><name><surname>Alkan</surname><given-names>A</given-names></name><name><surname>Aralasmak</surname><given-names>A</given-names></name><name><surname>Oktem</surname><given-names>F</given-names></name></person-group><article-title>Reversible corpus callosum splenial lesion due to steroid therapy</article-title>. <source>J Neuroimaging</source><year>2015</year>; <volume>25</volume>:<fpage>501</fpage>–<lpage>504</lpage>.<pub-id pub-id-type="pmid">24945326</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>Yu</surname><given-names>CY</given-names></name></person-group><article-title>Reversible focal splenium lesion—MRS study of a different etiology</article-title>. <source>Acta Neurol Taiwan</source><year>2009</year>; <volume>18</volume>:<fpage>203</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">19960965</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsubouchi</surname><given-names>Y</given-names></name><name><surname>Itamura</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Use of high <italic>b</italic> value diffusion-weighted magnetic resonance imaging in acute encephalopathy/encephalitis during childhood</article-title>. <source>Brain Dev</source><year>2018</year>; <volume>40</volume>:<fpage>116</fpage>–<lpage>125</lpage>.<pub-id pub-id-type="pmid">28838686</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Baralc</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Mild encephalopathy/encephalitis with a reversible splenial lesion (MERS): a report of five neonatal cases</article-title>. <source>J Huazhong Univ Sci Technol Med Sci</source><year>2017</year>; <volume>37</volume>:<fpage>433</fpage>–<lpage>438</lpage>.<pub-id pub-id-type="pmid">28585150</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osuka</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Mild encephalitis/encephalopathy with a reversible splenial lesion: evaluation by diffusion tensor imaging. Two case reports</article-title>. <source>Neurol Med Chir (Tokyo)</source><year>2010</year>; <volume>50</volume>:<fpage>1118</fpage>–<lpage>1122</lpage>.<pub-id pub-id-type="pmid">21206192</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badaut</surname><given-names>J</given-names></name><name><surname>Fukuda</surname><given-names>AM</given-names></name><name><surname>Jullienne</surname><given-names>A</given-names></name><name><surname>Petry</surname><given-names>KG</given-names></name></person-group><article-title>Aquaporin and brain diseases</article-title>. <source>Biochim Biophys Acta</source><year>2014</year>;<volume>1840</volume>:<fpage>1554</fpage>–<lpage>1565</lpage>.<pub-id pub-id-type="pmid">24513456</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Interleukin-1beta induces the expression of aquaporin-4 through a nuclear factor-kappaB pathway in rat astrocytes</article-title>. <source>J Neurochem</source><year>2006</year>; <volume>99</volume>:<fpage>107</fpage>–<lpage>118</lpage>.<pub-id pub-id-type="pmid">16987239</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Zador</surname><given-names>Z</given-names></name><name><surname>Verkman</surname><given-names>AS</given-names></name></person-group><article-title>Glial cell aquaporin-4 overexpression in transgenic mice accelerates cytotoxic brain swelling</article-title>. <source>J Biol Chem</source><year>2008</year>; <volume>283</volume>:<fpage>15280</fpage>–<lpage>15286</lpage>.<pub-id pub-id-type="pmid">18375385</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>JA</given-names></name><name><surname>Hsu</surname><given-names>MS</given-names></name><name><surname>Seldin</surname><given-names>MM</given-names></name><name><surname>Binder</surname><given-names>DK</given-names></name></person-group><article-title>Expression of the astrocyte water channel aquaporin-4 in the mouse brain</article-title>. <source>ASN Neuro</source><year>2015</year>; <volume>7</volume>:pii: 1759091415605486.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>ZP</given-names></name></person-group><article-title>Reperfusion of the rat brain tissues following acute ischemia: the correlation among diffusion-weighted imaging, histopathology, and aquaporin-4 expression</article-title>. <source>Chin Med J</source><year>2011</year>; <volume>124</volume>:<fpage>3148</fpage>–<lpage>3153</lpage>.<pub-id pub-id-type="pmid">22040570</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Bian</surname><given-names>J</given-names></name></person-group><article-title>Aquaporin-4 knockdown ameliorates hypoxic-ischemic cerebral edema in newborn piglets</article-title>. <source>IUBMB Life</source><year>2015</year>; <volume>67</volume>:<fpage>182</fpage>–<lpage>190</lpage>.<pub-id pub-id-type="pmid">25857369</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katada</surname><given-names>R</given-names></name><name><surname>Nishitani</surname><given-names>Y</given-names></name><name><surname>Honmou</surname><given-names>O</given-names></name><name><surname>Zhai</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Bian</surname><given-names>J</given-names></name></person-group><article-title>Expression of aquaporin-4 augments cytotoxic brain edema after traumatic brain injury during acute ethanol exposure</article-title>. <source>Am J Pathol</source><year>2012</year>; <volume>180</volume>:<fpage>17</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">22051773</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Sobue</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Hyperosmolar mannitol stimulates expression of aquaporins 4 and 9 through a p38 mitogen-activated protein kinase-dependent pathway in rat astrocytes</article-title>. <source>J Biol Chem</source><year>2003</year>; <volume>278</volume>:<fpage>44525</fpage>–<lpage>44534</lpage>.<pub-id pub-id-type="pmid">12944406</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro Mde</surname><given-names>C</given-names></name><name><surname>Hirt</surname><given-names>L</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name><name><surname>Regli</surname><given-names>L</given-names></name><name><surname>Badaut</surname><given-names>J</given-names></name></person-group><article-title>Time course of edema formation and brain aquaporin expression after transient focal cerebral ischemia in mice</article-title>. <source>J Cereb Blood Flow Metab</source><year>2005</year>; <volume>25</volume>:<fpage>S259</fpage>–<lpage>S259</lpage>.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colbran</surname><given-names>RJ</given-names></name></person-group><article-title>Regulation and role of brain calcium/calmodulin-dependent protein kinase II</article-title>. <source>Neurochem Int</source><year>1992</year>; <volume>21</volume>:<fpage>469</fpage>–<lpage>497</lpage>.<pub-id pub-id-type="pmid">1338943</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>VJ</given-names></name><name><surname>Tsujita</surname><given-names>M</given-names></name><name><surname>Kwee</surname><given-names>IL</given-names></name><name><surname>Nakada</surname><given-names>T</given-names></name></person-group><article-title>Inhibition of aquaporin 4 by antiepileptic drugs</article-title>. <source>Bioorg Med Chem</source><year>2009</year>; <volume>17</volume>:<fpage>418</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">18178093</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>A round ROI (58 mm<sup>2</sup>) is automatically generated by Functool-ADC software (General Electric Healthcare, Milwaukee, IL, USA). The ROI is carefully copied and placed in the center of the genu and splenium of the corpus callosum. The location of the ROIs was jointly confirmed by two radiologists. (<bold>a</bold>) The location of ROIs in the initial examination. (<bold>b</bold>) The location of ROIs in the follow-up examination. ADC, apparent diffusion coefficient.</p></caption><graphic xlink:href="mrms-19-14-g1"></graphic></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Shape of SCC lesions in MERS type I; (<bold>a</bold>) circle shape, (<bold>b</bold>) oval shape, (<bold>c</bold>) boomerang shape. There is no visible reduced diffusion in the genu. SCC, splenium of the corpus callosum; MERS, mild encephalitis/encephalopathy with a reversible splenial.</p></caption><graphic xlink:href="mrms-19-14-g2"></graphic></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>SPSS box plots showing the median, four quantiles, maximum, and minimum ADC values from 92 regions of interest (23 MERS type I patients) for four sets of data: initial examination of SCC (group 1, 23 ROIs); follow-up examination of SCC after treatment (group 2, 23 ROIs); initial examination of GCC (group 3, 23 ROIs); follow-up examination of GCC after treatment (group 4, 23 ROIs). Numbers in the box plots indicated the patient No. (corresponding to <xref rid="T1" ref-type="table">Table 1</xref>). ADC, apparent diffusion coefficient; SCC, splenium of the corpus callosum; GCC, genu of the corpus callosum; asterisk, the extreme value of the data group; circle, the outlier value of the data group; MERS, mild encephalitis/encephalopathy with a reversible splenial.</p></caption><graphic xlink:href="mrms-19-14-g3"></graphic></fig><fig id="F4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Magnetic resonance images from a 23-year-old man presenting with headache. (<bold>a</bold> and <bold>b</bold>) Axial DWI and ADC map showing reduced diffusion in the splenium (arrows), which is a typical MERS type I presentation. There is no visible reduced diffusion in the genu. (<bold>c</bold> and <bold>d</bold>) Follow-up axial DWI and ADC map after 10 days of symptomatic treatment, showing that the lesions had disappeared. DWI: diffusion-weighted imaging; ADC: apparent diffusion coefficient; MERS, mild encephalitis/encephalopathy with a reversible splenial.</p></caption><graphic xlink:href="mrms-19-14-g4"></graphic></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Basic information for 23 patients included in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Patient No.</th><th align="center" valign="middle" rowspan="1" colspan="1">Age (years)</th><th align="center" valign="middle" rowspan="1" colspan="1">Sex</th><th align="center" valign="middle" rowspan="1" colspan="1">Cause of MERS</th><th align="center" valign="middle" rowspan="1" colspan="1">Days from symptom onset to initial MR examination</th><th align="center" valign="middle" rowspan="1" colspan="1">Days from follow-up to initial MR examination</th><th align="center" valign="middle" rowspan="1" colspan="1">Type of MERS</th><th align="center" valign="middle" rowspan="1" colspan="1">Shape of MERS in SCC</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">4</td><td align="right" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="right" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">4</td><td align="right" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Boomerang</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Circle</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="right" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">4</td><td align="right" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="right" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Mycoplasmal encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Boomerang</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="right" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">6</td><td align="right" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Boomerang</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="right" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Viral meningoencephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">7</td><td align="right" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="right" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="right" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Central nervous system infection</td><td align="right" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="right" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Viral meningitis</td><td align="right" valign="top" rowspan="1" colspan="1">2</td><td align="right" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Circle</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="right" valign="top" rowspan="1" colspan="1">17</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Central nervous system infection</td><td align="right" valign="top" rowspan="1" colspan="1">5</td><td align="right" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Circle</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="right" valign="top" rowspan="1" colspan="1">21</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Thyroid storm</td><td align="right" valign="top" rowspan="1" colspan="1">6</td><td align="right" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="right" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Eclampsia (Iatrogenic drugs)</td><td align="right" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">14</td><td align="right" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">5</td><td align="right" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Circle</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="right" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Tuberculosis hemoptysis (Iatrogenic drugs)</td><td align="right" valign="top" rowspan="1" colspan="1">5</td><td align="right" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Circle</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">16</td><td align="right" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Circle</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="right" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Brain injury</td><td align="right" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">29</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="right" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Hemorrhagic fever with renal syndrome</td><td align="right" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="right" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">2</td><td align="right" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="right" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Central nervous system infection</td><td align="right" valign="top" rowspan="1" colspan="1">11</td><td align="right" valign="top" rowspan="1" colspan="1">12</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">21</td><td align="right" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Viral encephalitis</td><td align="right" valign="top" rowspan="1" colspan="1">3</td><td align="right" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">22</td><td align="right" valign="top" rowspan="1" colspan="1">55</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Hypoglycemia</td><td align="right" valign="top" rowspan="1" colspan="1">4</td><td align="right" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Olivary</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">23</td><td align="right" valign="top" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">Diabetes complicated with chronic renal insufficiency</td><td align="right" valign="top" rowspan="1" colspan="1">1</td><td align="right" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">I</td><td align="center" valign="top" rowspan="1" colspan="1">Circle</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>MERS: mild encephalitis/encephalopathy with a reversible splenial lesion; SCC: splenium of the corpus callosum.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical data of patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Etiologic group and serum sodium</th><th align="center" valign="middle" rowspan="1" colspan="1">No. of patients (%)</th><th align="center" valign="middle" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" rowspan="1" colspan="1">Clinical outcomes</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Infectious disease</td><td align="left" valign="top" rowspan="1" colspan="1">17 (73.91)</td><td align="center" valign="top" rowspan="1" colspan="1">Anti-virus, anti-infection, symptomatic treatment</td><td align="center" valign="top" rowspan="1" colspan="1">CR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Central nervous system infection</td><td align="left" valign="top" rowspan="1" colspan="1">16 (69.57)</td><td align="center" valign="top" rowspan="1" colspan="1">Anti-virus, Anti-infection, symptomatic treatment</td><td align="center" valign="top" rowspan="1" colspan="1">CR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systemic infection (hemorrhagic fever with renal syndrome)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.35)</td><td align="center" valign="top" rowspan="1" colspan="1">Anti-virus, symptomatic treatment</td><td align="center" valign="top" rowspan="1" colspan="1">CR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Metabolic-related diseases (diabetes, hypoglycemia, etc.)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (13.04)</td><td align="center" valign="top" rowspan="1" colspan="1">Correct electrolyte and blood sugar</td><td align="center" valign="top" rowspan="1" colspan="1">CR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Acute craniocerebral injury</td><td align="left" valign="top" rowspan="1" colspan="1">1 (4.35)</td><td align="center" valign="top" rowspan="1" colspan="1">Epidural hematoma removal, symptomatic treatment</td><td align="center" valign="top" rowspan="1" colspan="1">CR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Iatrogenic drugs</td><td align="left" valign="top" rowspan="1" colspan="1">2 (8.70)</td><td align="center" valign="top" rowspan="1" colspan="1">Suspend use of drug</td><td align="center" valign="top" rowspan="1" colspan="1">CR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hyponatremia</td><td align="left" valign="top" rowspan="1" colspan="1">6 (26.09)</td><td align="center" valign="top" rowspan="1" colspan="1">Correct electrolyte</td><td align="center" valign="top" rowspan="1" colspan="1">CR</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>CR, complete recovery.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Lesion classification and morphology in the initial MR image of 23 cases of clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Itemize</th><th align="center" valign="top" rowspan="1" colspan="1">DWI</th><th align="center" valign="top" rowspan="1" colspan="1">ADC-map</th><th colspan="3" align="center" valign="top" rowspan="1">Lesion shape</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"><hr></hr></th><th colspan="2" align="center" valign="top" rowspan="1"><hr></hr></th><th colspan="3" align="center" valign="top" rowspan="1"><hr></hr></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">MR feature</th><th align="center" valign="top" rowspan="1" colspan="1">High</th><th align="center" valign="top" rowspan="1" colspan="1">Low</th><th align="center" valign="top" rowspan="1" colspan="1">Circle</th><th align="center" valign="top" rowspan="1" colspan="1">Olivary</th><th align="center" valign="top" rowspan="1" colspan="1">Boomerang</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Number of cases</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ratio (%)</td><td align="center" valign="top" rowspan="1" colspan="1">100.0</td><td align="center" valign="top" rowspan="1" colspan="1">100.0</td><td align="center" valign="top" rowspan="1" colspan="1">30.43</td><td align="center" valign="top" rowspan="1" colspan="1">56.52</td><td align="center" valign="top" rowspan="1" colspan="1">13.04</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Mean ADC value and results of paired samples <italic>t</italic>-test on the same region of interest in the SCC and GCC before and after the treatment of 23 cases of clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Location</th><th align="center" valign="middle" rowspan="1" colspan="1">The initial examination (10<sup>−3</sup> mm<sup>2</sup>/s)</th><th align="center" valign="middle" rowspan="1" colspan="1">Follow-up examination (10<sup>−3</sup> mm<sup>2</sup>/s)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>t</italic></th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SCC</td><td align="center" valign="top" rowspan="1" colspan="1">0.448 ± 0.124</td><td align="center" valign="top" rowspan="1" colspan="1">0.790 ± 0.070</td><td align="center" valign="top" rowspan="1" colspan="1">−12.157</td><td align="center" valign="top" rowspan="1" colspan="1">3.096 × 10<sup>−11</sup></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GCC</td><td align="center" valign="top" rowspan="1" colspan="1">0.783 ± 0.067</td><td align="center" valign="top" rowspan="1" colspan="1">0.829 ± 0.070</td><td align="center" valign="top" rowspan="1" colspan="1">−4.780</td><td align="center" valign="top" rowspan="1" colspan="1">9.000 × 10<sup>−5</sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>Results are shown as mean ± standard deviation. ADC, apparent diffusion coefficient; SCC, splenium of the corpus callosum; GCC, genu of the corpus callosum.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F14 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000F14 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7067916
|texte= Statistical Analysis of the Apparent Diffusion Coefficient in Patients with Clinically Mild Encephalitis/Encephalopathy with a Reversible Splenial Lesion Indicates That the Pathology Extends Well beyond the Visible Lesions
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:30956273" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |